Enjoy complimentary customisation on priority with our Enterprise License!
According to the leukemia therapeutics industry insights at Technavio, the leukemia therapeutics market will witness fast-paced growth and will post a staggering CAGR of more than 8% over the forecast period. The application for expanded indication approvals is one of the primary factors driving the growth of this market. The concept of repositioning came into practice in the early 1990s and is based on the possibility that different diseases could be sharing common molecular pathways. This has led several companies to conduct clinical trials to determine the effectiveness of the drugs in all such related indications. As this process of drug re-positioning leading to extended indication is a low-risk, high-reward strategy, it could increase the scope of treatment and help in increased market penetration.
One of the recent leukemia therapeutics market trends propelling the growth prospects for this market is the rise in the development of combination therapies to treat leukemia. Combination therapies for the treatment of leukemia are mostly available in the form of combination chemotherapy drugs. Some of the approved combinations include chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of chronic lymphocytic leukemia (CLL); a combination of cytarabine, daunorubicin, and etoposide for the treatment of acute myeloid leukemia (AML); and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of acute lymphocytic leukemia (ALL). These therapies are expected to increase the effectiveness of the treatment, which in turn, will increase the patient compliance toward the use of these drugs.
The leukemia therapeutics market characterized by the presence of several well-established vendors. The market is growing steadily because of an augmented demand for leukemia drugs, which is also expected to boost R&D activities. The vendors are manufacturing and selling drugs that can effectively treat the disease, and also possess a high efficacy and safety profile. This is expected to help the vendors to gain a competitive edge over their peers.
Key vendors in this market are
Other prominent vendors in the market include Altor BioScience, Ambit BioSciences, Amgen, Ariad Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene Corporation, CTI Biopharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme Corp, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, Meda, MedImmune, Merck, Midas Pharmaceuticals, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.
The global CML therapeutics segment is one of the fastest growing segments of the market and is expected to reach over USD 5 billion by 2020. Factors such as the increasing use of combination therapies and the introduction of several breakthrough drugs in the market will drive this segment’s growth in the coming years.
In terms of geography, the Americas led the leukemia therapeutics market and is anticipated to reach close to USD 7 billion in 2020. The US is the largest revenue contributor in the region. The growth of this market in the region is attributed to the high prevalence of the disease in the region. According to several research studies, nearly 61,000 new cases of leukemia will be diagnosed in the US in 2016, of which 20,000 cases will be of AML. Furthermore, the presence of patient assistance programs by government and non-government organizations in the US are also expected to drive market growth. As drugs such as Iclusig, Rituxan, and Arzerra are costly, patient withdrawal from the treatment regimen is common. Instead, end-users prefer affordable generic medication such as generic imatinib. However, the availability of patient assistance programs from vendors and other government and non-government organizations will help decrease non-compliance among individuals and increase the demand for branded TKIs.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
PART 07: Market segmentation by disease type
PART 08: Global CLL therapeutics market
PART 09: Global ALL therapeutics market
PART 10: Global AML therapeutics market
PART 11: Global CML therapeutics market
PART 12: Geographical segmentation
PART 13: Market drivers
PART 14: Impact of drivers
PART 15: Market challenges
PART 16: Impact of drivers and challenges
PART 17: Market trends
PART 18: Vendor landscape
PART 19: Key vendor analysis
PART 20: Appendix
PART 21: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.